Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy
收藏官方服务：
资源简介：
Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy
应用场景：
创建时间：
2026-07-01
相关数据集
Dataset from A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 p
NIAID Data Ecosystem20
Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis
All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering ag
DataCite Commons2025-02-10 更新10
Additional file 7: of Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
Cell subsets related to miRNA expression level, as measured by OpenArray or qPCR assay. In this additional analysis, miRNA expression levels are compared with FACS results on PBMC cell subsets. (XLSX
Figshare2016-12-14 更新10
Summary of details from MTX users for RA who exhibited ALT/AST levels > 3 times the ULN during a 1-year follow-up period.
Summary of details from MTX users for RA who exhibited ALT/AST levels > 3 times the ULN during a 1-year follow-up period.
Figshare2018-08-24 更新20
Logistic regression model to predicting 6th month moderate EULAR response to BCDT in RA patients.
The cut-off values for continuous variables related to the “moderate-EULAR response to BCDT after 6th months FU” were obtained with ROC curves analysis. OR = odds ratio; 95%CI = 95% confidence interva
Figshare2015-12-02 更新10
